BenevolentAI Investor Presentation Deck
Cash runway to at least end-2024 providing sufficient
capital for next stage of growth
Pro Forma cash
BenevolentAl Cash¹
Odyssey cash held in trust
PIPE
Cash Runway
Transaction fees4
Total Pro Forma Cash
€m
€ 48
€ 89
€ 136
(€58)
€ 215
Benevolent
5
Capital allocation
Fund Phase I/II trial for PanTrk in Atopic Dermatitis
(before subsequent out-license)
Fund Phase I trial for PDE10 in Ulcerative Colitis and
commencement of Phase II trial in 2024
Target funding 5 further Phase I trials and readouts by
2025
A technology platform continually innovating to
accelerate our global leadership in Al-enabled Drug
Discovery
Invest in the operational platform to support listing
status and further collaboration agreements
Source: Company information
Notes:. (1) £40.6m, as of 31 December 2021 (2) €80m Equity Commitments secured, to ensure that minimum cash requirement for closing will be met and Transaction close certainty is increased (3) Assumes no share redemptions from Odyssey shareholders;
(4) Expenses for both SPAC and target including deferred underwriting fees, PIPE fee, financing fees, and advisory, legal, accounting and other fees.
Benevolent 17View entire presentation